Source: International Congress 2015 – Lung function: exploring the boundaries of the respiratory system
Disease area: Interstitial lung diseases

Abstract

Background: Bleomycin induced pulmonary toxicity is clinically detected using diffusing lung capacity for carbon monoxide (DLCO) in Hodgkin's Lymphoma (HL) patients after chemotherapy.Objective: To evaluate changes in DLCO in HL patients after ABVD chemotherapy.Methods: Medical records of all adult HL patients treated with ABVD chemotherapy at a single center in Lahore, Pakistan during the entire calendar year 2012 were analyzed. Patients with pre-existing pulmonary dysfunction, history of thoracic surgery and smokers were excluded.Results: Out of 179 patients, 93 (51.95%) patients had received both a pre- and post-chemotherapy DLCO. The mean percentage difference between pre- and post-chemotherapy values for DLCO (5.49%; 95% confidence interval [CI] 1.56%-9.43%) and for Hemoglobin-adjusted DLCO (8.24%; 95% CI 3.90%-12.57%) were statistically significant at p<0.01. After adjusting for age, a 1mg/m² increase in dose of Bleomycin was significantly associated with 0.14% (95% CI: 0.03%-0.25%) decline in DLCO and 0.13% (95% CI: 0.10%-0.26%) decline in hemoglobin-adjusted DLCO from pretreatment value.

Paired comparison of Diffusion Lung capacity

		p-value
Pre and post DLCO		0.007
Pre and post Hemoglobin adjusted DLCO		0.001
Pre and post alveolar volume adjusted DLCO		0.001
Pre and post Hemoglobin and alveolar volume adjusted DLCO		0.001

 

Conclusions: Mild to moderate dysfunction in diffusion lung capacity is common after ABVD chemotherapy.


Rating:

Share or cite this content

Citations should be made in the following way:
muhammad Abdullah (lahore, Pakistan), Muhammad Abdullah, Shoaib Alam, Waleed Zafar, Abdul Majid, Ali Saeed Wahla. Diffusion lung capacity changes in Hodgkin lymphoma patients before and after ABVD chemotherapy. Eur Respir J 2015; 46: Suppl. 59, 963

Member's Comments

No comment yet.

Related content which might interest you: Lung adenocarcinoma mimicking interstitial lung disease showed good response to navelbine monotherapy Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Novel lung function tests in patients with interstitial lung disease (ILD) Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Surfactant protein-D level as a predictor of prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer Source: International Congress 2016 – Orphan diseases I Year: 2016 Pulmonary function changes after chemotherapy and radiotherapy for Lymphoma. Source: International Congress 2017 – Case reports and series Year: 2017 Lung resistance-related protein in lung cancer and lung lesions in Hodgkin disease Source: Eur Respir J 2006; 28: Suppl. 50, 86s Year: 2006 Does CRP predicts severity of hospitalized patients with diffuse interstitial lung disease? Source: International Congress 2014 – ILDs 5 Year: 2014 A case of Non-Hodgkin lyphoma mimicking diffuse parenchymal lung disease Source: International Congress 2016 – The best clinical approach to lung diseases Year: 2016 Does hypoxemia increases risks in hospitalized patients with diffuse interstitial lung disease? Source: International Congress 2014 – ILDs 6 Year: 2014 Clinical characteristics of patients with unclassifiable interstitial lung disease Source: International Congress 2015 – New insights into IIPs Year: 2015 Pemetrexed in advanced non-small cell lung cancer patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 The role of CCR2+CD4+T cells in lung fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 A case series of eight patients treated with alectinib including a case of interstitial lung disease Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016 Beneficial effect of azithromycin in children with diffuse parenchymal lung disease Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Annual changes in pulmonary function are independent prognostic factors for the patients with chronic hypersensitivity pneumonia Source: International Congress 2014 – ILDs 3 Year: 2014 Pulmonary function changes during treatment with rituximab in patients with rheumatoid arthritis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Incidence of interstitial lung disease (ILD) and risk factors for developing ILD: A final analysis of a large-scale erlotinib Japanese surveillance study in non-small-cell lung cancer (NSCLC) Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 What predicts radiation pneumonitis best? Pulmonary injury after curatively intended radiotherapy of early-stage lung cancer Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016 Clinical characteristic of lung cancer patients with interstitial pneumonia treated with chemotherapy or radiotherapy Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Our results of stereotactic radiotherapy in advanced stage lung cancer patients Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014